CClinicalTrials.gg
CompletedNCT00885339Updated Jul 31, 2019

Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure

An observational study in Colonic Diseases, sponsored by Medtronic - MITG. Completed at 4 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by Medtronic - MITG · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare two preparation and procedure in order to develop the most optimal capsule procedure in regards to colon cleansing level and capsule excretion rate.

Read the detailed description

The evaluation of subjects with suspected colonic disease includes endoscopic imaging by colonoscopy and radiologic imaging such as air-contrast barium enema, or CT colonography. The PillCam platform offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, an ingestible device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the PillCam platform include the elimination of the need for sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the PillCam platform may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon and comply with colorectal cancer screening recommendations.

The PillCam™ SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 500,000 people worldwide and is well accepted by patients and physicians as well as the processional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. This is expected to improve the capability of the PillCam platform to detect colonic pathologies and to serve as a diagnostic and screening tool for colonic disease. Further details of the PillCam™ Colon Capsule Endoscope (PCCE) can be found in the device description section.

This is a pilot study that is designed to compare the levels of cleanliness and visualization of colon achieved by colon capsule endoscopy when using two different regimens for preparation of the colon. Furthermore, capsule colonoscopy and colonoscopy procedures will be compared in regards to the level of colon cleanliness and detection of lesions in the colon. The study will be conducted in 2 phases: pilot phase in which the optimal procedure will be determined following a comparison of the two procedures. The second phase will be a validation of the proposed procedure.

02

Conditions studied

  • Colonic Diseases

Browse trials for

Keywords

  • Colonic Diseases
03

In context

Colonic Diseases

142 studies on the registry are indexed under Colonic Diseases; 22 are open to participants now.

This study's planned enrollment of 100 is below the median of 170 across 48 observational studies indexed under Colonic Diseases.

Browse Colonic Diseases studies →

Lead sponsor

Medtronic - MITG is the lead sponsor of 176 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases

Inclusion criteria

  • Subject is between the ages of 18-75 years.
  • Subject is referred for colonoscopy as clinically indicated for any reason. This may include, but not limited to, the investigation of any of the following conditions: rectal bleeding, melena, positive stool testing for occult blood, recent change of bowel habits, screening for colorectal cancer, ulcerative colitis, colonic findings on an imaging study)

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from study enrollment:

  • Subject has dysphagia or any swallowing disorder
  • Subject has Congestive heart failure
  • Subject has high degree of renal insufficiency
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator
  • Subject has a cardiac pacemaker or other implanted electromedical device.
  • Subject has any allergy or other known contraindication to the medications used in the study
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject with any condition believed to have an increased risk for capsule retention such as Crohn's disease, intestinal tumors, radiation enteritis, or NSAID enteropathy,
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
  • Subject suffers from life threatening conditions
  • Subject currently participating in another clinical study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)

Groups and cohorts

  • A

    Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.

06

What researchers measure

Primary outcomes

  1. Colon cleansing level score

    Time frame: within 7 days

  2. Number of colon capsules excreted over time

    Time frame: within 7 days

Secondary outcomes

  1. Accuracy parameters of PCCE, compared to colonoscopy.

    Time frame: within 7 days

  2. Number, type and severity of adverse events

    Time frame: within 7 days

  3. Patient subjective assessment questionnaires

    Time frame: within 7 days

  4. Physician assessment questionnaire

    Time frame: within 7 days

07

Study locations

4 sites
  • Centro Ricerca e Formazione ad Alta Tecnologia nelle Scienze Bomediche
    Campobasso, 86100, Italy
  • Humanitas Istituto Clinico
    Milano, 20089, Italy
  • Ospedale Maggiore - Policlinico
    Milano, 2100, Italy
  • Universita Cattolica del Sacro Cuore
    Roma, 00168, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00885339
Lead sponsor
Medtronic - MITG
Responsible party
Sponsor
First posted
Apr 21, 2009
Start date
Feb 2008
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Jul 31, 2019

Study contacts

Guido Costamagna, Prof. Dr.
principal investigator · Catholic University of the Sacred Heart

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion